WASHINGTON, June 27, 2016 - Baker Botts L.L.P., a leading international law firm, announced today that its client, Boehringer Ingelheim GmbH, one of the world’s leading pharmaceutical companies focusing on researching, developing, and marketing human health and animal health products, signed a contract with Sanofi to secure a significant business swap initiated in December 2015. The strategic swap consists of an exchange of Sanofi’s animal health business (“Merial”) and Boehringer Ingelheim’s consumer healthcare (CHC) business. The parties announced today in a joint statement that the deal is expected to close by year-end 2016.
Baker Botts is advising Boehringer Ingelheim GmbH on the U.S. antitrust review of the transaction.
For more information, please see Boehringer Ingelheim’s news release by clicking here.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 700 lawyers practicing throughout a network of 13 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the technology, energy, and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.